Synuclein

Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB

Retrieved on: 
Monday, May 17, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Branches of biology, Peripheral membrane proteins, Neurological disorders, Alpha-synuclein, Lewy body dementia, Synuclein, Neurodegeneration, UCB

b'Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson\xe2\x80\x99s Disease.

Key Points: 
  • b'Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson\xe2\x80\x99s Disease.
  • UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies, Inc and UCB Biopharma SRL on December 31, 2014.
  • We believe that inhibition of alpha-synuclein misfolding and oligomerization with an orally active, brain penetrating, small molecule represents a promising therapeutic approach.
  • As a result of this latest milestone achievement, Neuropore Therapies has cumulatively received $63 million (USD) of the potential $460 million (USD) in total milestones available through its collaboration with UCB.\nParkinson\xe2\x80\x99s disease (PD) is the second most common neurodegenerative disorder after Alzheimer\xe2\x80\x99s disease.

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early Parkinson’s Disease

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Peripheral membrane proteins, Health, Clinical research, Design of experiments, Lewy body dementia, Alpha-synuclein, Neuropathology, Clinical trial, Parkinson's disease, Synuclein, Placebo-controlled study

PADOVA is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of prasinezumab in patients with early Parkinson\xe2\x80\x99s disease who are on stable symptomatic medication.

Key Points: 
  • PADOVA is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of prasinezumab in patients with early Parkinson\xe2\x80\x99s disease who are on stable symptomatic medication.
  • The study will enroll approximately 575 patients, who will be randomized to receive either prasinezumab or placebo via intravenous infusion every 4 weeks.
  • Prasinezumab is designed to block the cell-to-cell transmission of the aggregated, pathogenic forms of alpha-synuclein in Parkinson's disease, thereby slowing clinical decline.
  • Prior to initiating clinical trials, the efficacy of prasinezumab was evaluated in various cellular and animal models of alpha-synuclein-related disease.

SciNeuro Pharmaceuticals Announces Exclusive Licensing Agreement with Eli Lilly & Company

Retrieved on: 
Wednesday, April 14, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Life sciences, Peripheral membrane proteins, Health sciences, Branches of biology, Alpha-synuclein, Lewy body dementia, Eli Lilly and Company, Biopharmaceutical, Synuclein, Pharmaceutical industry in China, Eli Lilly and Company, SciNeuro Pharmaceuticals

b'SciNeuro Pharmaceuticals , an innovative biopharmaceutical company focused on delivering transformative therapies to patients with neurological diseases, has entered into an exclusive license agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.\nUnder the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China.

Key Points: 
  • b'SciNeuro Pharmaceuticals , an innovative biopharmaceutical company focused on delivering transformative therapies to patients with neurological diseases, has entered into an exclusive license agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of alpha-synuclein targeted antibody therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.\nUnder the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China.
  • Lilly will receive an upfront cash payment, in addition to downstream milestones and royalties on products developed and commercialized by SciNeuro.
  • Lilly retains all rights outside Greater China.\n\xe2\x80\x9cApproximately 3 million elderly people are currently affected by Parkinson\xe2\x80\x99s disease in Greater China, creating a significant disease burden.
  • Located in the major life sciences hubs of Shanghai and Philadelphia, SciNeuro is establishing a robust CNS product pipeline through internal innovation and global partnerships.

Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference

Retrieved on: 
Monday, February 22, 2021
Branches of biology, Peripheral membrane proteins, Lewy body dementia, Neurodegenerative disorders, Psychiatric diagnosis, Alpha-synuclein, Parkinson's disease, Synuclein

These outcomes suggest a mechanistic understanding of the role of alpha-synuclein plaques in the onset of disease.

Key Points: 
  • These outcomes suggest a mechanistic understanding of the role of alpha-synuclein plaques in the onset of disease.
  • Details for the presentation are below:
    Following the presentation, there will be a live panel discussion and Q&A session from 11:00-11:15am ET.
  • "We are excited to share some of the preclinical results of our IkT-148009 program at the ASENT 2021 conference.
  • Inhibikase (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders.

Yumanity Therapeutics Provides Update on Its Lead Parkinson’s Disease Clinical Program, YTX-7739

Retrieved on: 
Wednesday, February 10, 2021
Branches of biology, Peripheral membrane proteins, Proteins, Alpha-synuclein, Lewy body dementia, Neurodegenerative disorders, Parkinson's disease, Synuclein, Parkinson

Multiple lines of evidence indicate that misfolded alpha-synuclein is a strong risk factor for Parkinsons disease.

Key Points: 
  • Multiple lines of evidence indicate that misfolded alpha-synuclein is a strong risk factor for Parkinsons disease.
  • We have completed the single ascending dose (SAD) study in healthy volunteers, which provides early evidence of the drug candidates safety and tolerability profile.
  • The Companys most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinsons disease.
  • Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007

Retrieved on: 
Monday, October 26, 2020
Branches of biology, Peripheral membrane proteins, Neuropathology, Synuclein, Lewy body dementia, Alpha-synuclein

This patent covers the composition of matter comprising at least one inhibitory peptide that inhibits -synuclein aggregation by binding to residues 68-78 of -synuclein.

Key Points: 
  • This patent covers the composition of matter comprising at least one inhibitory peptide that inhibits -synuclein aggregation by binding to residues 68-78 of -synuclein.
  • As previously announced, Seelos is currently conducting an in vivo preclinical study of SLS-007.
  • The preclinical study is designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement parameters of SLS-007.
  • Recent in vitro and cell culture research have shown that SLS-007 has the potential to stop the propagation and seeding of -synuclein aggregates.

Roche and Prothena will Advance Prasinezumab into Late-Stage Clinical Development Study in Parkinson’s Disease

Retrieved on: 
Tuesday, October 20, 2020
Branches of biology, Health, Peripheral membrane proteins, Lewy body dementia, Medical specialties, Alpha-synuclein, Geriatrics, Psychiatric diagnosis, RTT, Parkinson's disease, Clinical trial, Synuclein

Prothena will earn a $60 million clinical milestone payment upon first patient dosed in this study.

Key Points: 
  • Prothena will earn a $60 million clinical milestone payment upon first patient dosed in this study.
  • Prasinezumab is designed to block the cell-to-cell transmission of the aggregated, pathogenic forms of alpha-synuclein in Parkinson's disease, thereby slowing clinical decline.
  • Prior to initiating clinical trials, the efficacy of prasinezumab was evaluated in various cellular and animal models of alpha-synuclein-related disease.
  • For more information on the Phase 2 PASADENA clinical study of prasinezumab in patients with early Parkinson's disease, visit clinicaltrials.gov and search NCT #03100149.

Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations

Retrieved on: 
Monday, August 3, 2020
Branches of biology, Proteins, Peripheral membrane proteins, Biology, Lewy body dementia, Neuropathology, Alpha-synuclein, Antibody, Synuclein, AbbVie, Tau protein

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie.
  • Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations.
  • Under the terms of the collaboration agreements, Voyager received upfront payments to perform research and preclinical development of vectorized antibodies directed against tau and alpha-synuclein.
  • Voyager is free to pursue vectorized antibody programs for tau and alpha-synuclein alone or in collaboration with another partner.

Michael J. Fox Foundation Announces Winners of the "Ken Griffin Alpha-synuclein Imaging Competition" to Develop Game-Changing Tool for Parkinson's Research

Retrieved on: 
Thursday, July 30, 2020
Branches of biology, Proteins, Peripheral membrane proteins, Biology, Lewy body dementia, Psychiatric diagnosis, RTT, The Michael J. Fox Foundation, Parkinson's disease, Synuclein, Alpha-synuclein

Fox Foundation in supporting the important research driven by these incredible teams at AC Immune, Mass General Brigham and Merck," said Griffin.

Key Points: 
  • Fox Foundation in supporting the important research driven by these incredible teams at AC Immune, Mass General Brigham and Merck," said Griffin.
  • The Ken Griffin Alpha-synuclein Imaging Competition builds on MJFF's longstanding support of alpha-synuclein tracer research.
  • Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.
  • In addition to funding more than $900 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure.

Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-007 in Parkinson's Disease

Retrieved on: 
Thursday, June 25, 2020
Peripheral membrane proteins, Branches of biology, Lewy body dementia, Alpha-synuclein, Neuropathology, Synuclein, Pharmacodynamics

This preclinical study is designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement parameters of SLS-007.

Key Points: 
  • This preclinical study is designed to establish the in vivo pharmacokinetic and pharmacodynamic profiles and target engagement parameters of SLS-007.
  • SLS-007 is a family of rationally designed peptidic inhibitors which target the NACore of -synuclein to inhibit protein aggregation in patients with PD.
  • This central segment of -synuclein termed NACore, that is comprised of residues 68-78, has a critical role in the aggregation and cytotoxicity of -synuclein.
  • The group's goal was to lay out a roadmap to advance drugs targeting alpha-synuclein proteins and increase their odds of success.